NYSE:ABT
Abbott Labs (ABT)
Financials 
Technical Analysis 
Sep 12, 2026, 12:00 amThis summary was created by AI, based on 13 opinions in the last 12 months.
Abbott Labs (ABT) has faced significant challenges over the past year, marked by declining stock performance and reduced growth expectations. While its recent acquisition aimed at expanding its cancer treatment portfolio is viewed positively, it is anticipated to take time before it becomes accretive to earnings. Analysts note that although growth has slowed and market share has been lost, the company's diagnostics and devices business shows signs of potential recovery. Despite these hurdles, many experts still consider ABT a high-quality name in the healthcare sector, highlighting its reasonable valuation compared to historic PE ratios and consistent dividend history. Overall, while caution is advised due to technical weaknesses and elevated competition, there remains an underlying belief in the stock's long-term viability.
Christine PooleChristine Poole
Christine PooleGenerally, don’t like to buy stocks when they hit all-time highs. He would wait for a better entry point. Great company. Not cheap but the multiple is not that extreme. (Analysts’ price target is $70.81)
Don Lato(A Top Pick May 17/17 Up 38%). He has been very happy with this. It has devices, diagnostics and pharma. The secular trends are positive with aging and obesity adding tailwinds. Their June acquisition was very accretive.
Cameron Hurst(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.
Cameron HurstShe continues to hold it and likes it. They have done well this year so she would wait for a pull back to add to this position. They are good at taking costs out. They always increase their dividend and it should continue. A good core holding.
Christine PooleHealthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)
Cameron Hurst'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
